Launch Sequencing
The strategic planning of the order a manufacturer introduces a treatment across national markets, influenced by international reference pricing linkages.
Pricing & Market Access
Terms for how medicine prices are set and negotiated and how patients gain access to new treatments.
- Topic: Pricing & Market Access
- 40 terms
- Editor reviewed
List PriceSticker Price, Catalogue Price
The publicly stated price a manufacturer offers a drug for sale, before accounting for negotiated discounts or rebates that reduce the price actually paid.
Managed Entry AgreementMEA, Access-with-Evidence Agreement
An arrangement governing the conditions under which a technology enters the market, often incorporating outcomes-based payment or coverage with evidence development.
Market AccessPatient Access Pathway, Reimbursement Access
The overall process by which a manufacturer secures favourable coverage, reimbursement, and clinical adoption for a new health technology.
Market Access StrategyMA Strategy, Access Strategy
A manufacturer's overall plan for achieving favourable coverage, reimbursement, and clinical adoption for a new treatment, integrating pricing and evidence generation.
Market ExclusivityMarketing Exclusivity, Data Exclusivity Period
A period during which regulators will not approve a competing generic or biosimilar, arising from patent protection, regulatory provisions, or both.
Negative ListDelisted Formulary, Non-Reimbursed List
A list of medications or services explicitly excluded from reimbursement coverage, unlike a positive list specifying what is covered.
Net PricePost-Rebate Price, Discounted Transaction Price
The actual price a manufacturer realises for a treatment after all rebates and discounts, distinct from its publicly listed gross price.